Lena Morrill Gavarró

Lena Morrill Gavarró

Auto-generated profile, based on publicly available information

Lena Morrill Gavarró

CRUK Cambridge Institute, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2017 in Nature Medicine
Verified
Journal Article
Open access
PDF file
LBLaura Broutier
Laura Broutier
GMGianmarco Mastrogiovanni
Gianmarco Mastrogiovanni
Monique M. A. VerstegenMonique M. A. Verstegen
Monique M. A. Verstegen
HFHayley E Francies
Hayley E Francies
LGLena Morrill Gavarró
Lena Morrill Gavarró
MHMeritxell Huch
Meritxell Huch
Tumor organoids derived from the most common subtypes of primary liver cancer recapitulate the histologic and molecular features of the tissues of origin, even after long-term culture. These in vitro models, as well as those for colorectal cancer reported in Crespo et al. in a previous issue, are amenable for drug screening and allow the identification of therapeutic approaches with potential for cancer treatment. Human liver cancer research currently lacks in vitro models that can faithfully recapitulate the pathophysiology of the original tumor. We recently described a novel, near-physiological organoid culture system, wherein primary human healthy liver cells form long-term expanding organoids that retain liver tissue function and genetic stability. Here we extend this culture system to the propagation of primary liver cancer (PLC) organoids from three of the most common PLC subtypes: hepatocellular carcinoma (HCC), cholangiocarcinoma (CC) and combined HCC/CC (CHC) tumors. PLC-derived organoid cultures preserve the histological architecture, gene expression and genomic landscape of the original tumor, allowing for discrimination between different tumor tissues and subtypes, even after long-term expansion in culture in the same medium conditions. Xenograft studies demonstrate that the tumorogenic potential, histological features and metastatic properties of PLC-derived organoids are preserved in vivo. PLC-derived organoids are amenable for biomarker identification and drug-screening testing and led to the identification of the ERK inhibitor SCH772984 as a potential therapeutic agent for primary liver cancer. We thus demonstrate the wide-ranging biomedical utilities of PLC-derived organoid models in furthering the understanding of liver cancer biology and in developing personalized-medicine approaches for the disease.

15 June 2022 in Nature
Verified
Journal Article
Closed access
PDF file
RDRuben M. Drews
Ruben M. Drews
BHBarbara Hernando
Barbara Hernando
MTMaxime Tarabichi
Maxime Tarabichi
KHKerstin Haase
Kerstin Haase
TLTom Lesluyes
Tom Lesluyes
FMFlorian Markowetz
Florian Markowetz

1 June 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
AJAlejandro Jiménez-Sánchez
Alejandro Jiménez-Sánchez
PCPaulina Cybulska
Paulina Cybulska
KMKatherine LaVigne Mager
Katherine LaVigne Mager
SKSimon Koplev
Simon Koplev
OCOliver Cast
Oliver Cast
MMMartin L. Miller
Martin L. Miller

20 July 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
PSPhilip Smith
Philip Smith
TBThomas Bradley
Thomas Bradley
LGLena Morrill Gavarró
Lena Morrill Gavarró
TGTeodora Goranova
Teodora Goranova
DEDarren P. Ennis
Darren P. Ennis
IMIain McNeish
Iain McNeish
The drivers of recurrence and resistance in ovarian high grade serous carcinoma remain unclear. We investigate the acquisition of resistance by collecting tumour biopsies from a cohort of 276 women with relapsed ovarian high grade serous carcinoma in the BriTROC-1 study. Panel sequencing shows close concordance between diagnosis and relapse, with only four discordant cases. There is also very strong concordance in copy number between diagnosis and relapse, with no significant difference in purity, ploidy or focal somatic copy number alterations, even when stratified by platinum sensitivity or prior chemotherapy lines. Copy number signatures are strongly correlated with immune cell infiltration, whilst diagnosis samples from patients with primary platinum resistance have increased rates of CCNE1 and KRAS amplification and copy number signature 1 exposure. Our data show that the ovarian high grade serous carcinoma genome is remarkably stable between diagnosis and relapse and acquired chemotherapy resistance does not select for common copy number drivers.

10 April 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ZCZhao Cheng
Zhao Cheng
HMHasan Mirza
Hasan Mirza
DEDarren P. Ennis
Darren P. Ennis
PSPhilip Smith
Philip Smith
LGLena Morrill Gavarró
Lena Morrill Gavarró
IMIain McNeish
Iain McNeish
Purpose: Ovarian high-grade serous carcinoma (HGSC) is usually diagnosed at late stage. We investigated whether late-stage HGSC has unique genomic characteristics consistent with acquisition of evolutionary advantage compared with early-stage tumors. Experimental Design: We performed targeted next-generation sequencing and shallow whole-genome sequencing (sWGS) on pretreatment samples from 43 patients with FIGO stage I–IIA HGSC to investigate somatic mutations and copy-number (CN) alterations (SCNA). We compared results to pretreatment samples from 52 patients with stage IIIC/IV HGSC from the BriTROC-1 study. Results: Age of diagnosis did not differ between early-stage and late-stage patients (median 61.3 years vs. 62.3 years, respectively). TP53 mutations were near-universal in both cohorts (89% early-stage, 100% late-stage), and there were no significant differences in the rates of other somatic mutations, including BRCA1 and BRCA2. We also did not observe cohort-specific focal SCNA that could explain biological behavior. However, ploidy was higher in late-stage (median, 3.0) than early-stage (median, 1.9) samples. CN signature exposures were significantly different between cohorts, with greater relative signature 3 exposure in early-stage and greater signature 4 in late-stage. Unsupervised clustering based on CN signatures identified three clusters that were prognostic. Conclusions: Early-stage and late-stage HGSCs have highly similar patterns of mutation and focal SCNA. However, CN signature analysis showed that late-stage disease has distinct signature exposures consistent with whole-genome duplication. Further analyses will be required to ascertain whether these differences reflect genuine biological differences between early-stage and late-stage or simply time-related markers of evolutionary fitness. See related commentary by Yang et al., p. 2730

11 May 2023 in eLife
Verified
Journal Article
Open access
MVMaria Vias
Maria Vias
LGLena Morrill Gavarró
Lena Morrill Gavarró
CSCarolin M Sauer
Carolin M Sauer
DSDeborah A Sanders
Deborah A Sanders
APAnna M Piskorz
Anna M Piskorz
JBJames D Brenton
James D Brenton
High-grade serous ovarian carcinoma (HGSOC) is the most genomically complex cancer, characterized by ubiquitous TP53 mutation, profound chromosomal instability, and heterogeneity. The mutational processes driving chromosomal instability in HGSOC can be distinguished by specific copy number signatures. To develop clinically relevant models of these mutational processes we derived 15 continuous HGSOC patient-derived organoids (PDOs) and characterized them using bulk transcriptomic, bulk genomic, single-cell genomic, and drug sensitivity assays. We show that HGSOC PDOs comprise communities of different clonal populations and represent models of different causes of chromosomal instability including homologous recombination deficiency, chromothripsis, tandem-duplicator phenotype, and whole genome duplication. We also show that these PDOs can be used as exploratory tools to study transcriptional effects of copy number alterations as well as compound-sensitivity tests. In summary, HGSOC PDO cultures provide validated genomic models for studies of specific mutational processes and precision therapeutics.